OCEANSIX-FUTURE-PATHS-LT
15.2.2024 15:22:35 CET | Business Wire | Press release
oceansix Files Provisional Patent for Groundbreaking Packaging System
oceansix Future Paths Ltd. ("the Company" or "oceansix") is a publicly-traded Company on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0). oceansix is a technology and manufacturing company on an environmental mission, using plastic waste to create innovative products and build transformative businesses. The company is headquartered in Israel and operates a research and development centre and a production facility in Valencia, Spain.
oceansix Announces the Filing of a Provisional Patent Application for an Innovative Package System
With a continuous commitment to executing its business plan, oceansix marks a significant milestone in its journey towards revolutionising e-commerce packaging. Filed earlier this year, this invention is poised to set new standards in packaging efficiency and reusable systems.
Innovative Design for Sustainable Impact
The package, conceptualised by inventor Gat Ramon, features a unique design that addresses the pressing environmental concerns of traditional single-use packaging. It also solves the critical challenges companies face in ensuring the protection of their items during transit without adding excessive weight or bulk, thereby optimising shipping efficiency.
The packaging is also engineered to adapt to various product sizes, eliminating the need for excess cushioning materials and significantly reducing waste. With its ecological nature, it was designed to be manufactured from recycled materials and to be reused for up to 100 cycles; therefore, it fully aligns with oceansix's mission to foster sustainable practices across industries, particularly businesses where packaging and e-commerce are at their highest peak.
Addressing E-Commerce Challenges
oceansix's package is specifically designed to mitigate the environmental impact of e-commerce, targeting the waste generated by cardboard and plastic materials. The project aims to reduce CO2 emissions and enhance reverse logistics efficiency and cost-effectiveness, offering a scalable and automated-compatible solution that incorporates future features like real-time location tracking and unique identification with smart locking.
oceansix Joins TheCircularLab's goCircular Radar for Circular Economy Excellence
oceansix is honoured to announce its inclusion in the goCircular Radar by TheCircularLab, Europe's pioneering circular economy innovation centre. This distinction places oceansix on the map of leading startups in Europe's circular economy sector, highlighting the reusable packaging project's potential and opening avenues for collaboration.
oceansix Enhances Strategy with Expert Collaboration and New Incentive Options
In addition to our recent announcement about the packaging system, oceansix has granted 300,000 options to a consultant, with a strike price of CAD 0.29, valid for five years. This initiative is a key component of our broader strategy to collaborate with experts whose insights and expertise are vital in propelling our mission forward.
Join oceansix
oceansix invites stakeholders, partners, and the global community to join in its vision of creating impactful and sustainable solutions.
For more information about oceansix and its pioneering projects, please visit oceansix.com and connect with us on LinkedIn.
About oceansix
oceansix Future Paths Ltd. is a leader in developing radical, sustainable solutions and transforming waste into innovative products. Driven by a circular model and a vision to tackle some of Earth's most pressing challenges, oceansix combines advanced technology with sustainable practices to create meaningful solutions and successful global businesses.
Disclaimer
This press release may contain forward-looking statements based on current expectations and assumptions, subject to risks and uncertainties. Actual results may differ materially from those anticipated in these statements. oceansix assumes no obligation to update or revise any forward-looking information.
Approval & Accuracy
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215233336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom